ASIA unversity:Item 310904400/115237
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 94286/110023 (86%)
造訪人次 : 21693944      線上人數 : 594
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋


    請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/115237


    題名: Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non–Small Cell Lung Cancer
    作者: Che, Wan-Ming;Chen, Wan-Ming;Che, Mingchih;Chen, Mingchih;Hs, Jeng-Guan;Hsu, Jeng-Guan;Tian-Shyug, L;Lee, Tian-Shyug;Sh, Ben-Chang;Shia, Ben-Chang;吳思遠;Wu, Szu-Yuan
    貢獻者: 醫學暨健康學院食品營養與保健生技學系
    日期: 2022-06-01
    上傳時間: 2023-03-29 01:05:52 (UTC+0)
    出版者: 亞洲大學
    摘要: Use of preoperative PET/CT was associated with lower risk of death in patients with stage IIIA–IIIB non–small cell lung cancer.

    Background
    The added value of preoperative PET/CT for the overall survival of patients with resectable non–small cell lung cancer (NSCLC) is unknown.

    Purpose
    To investigate the association of the use of preoperative PET/CT on survival of patients with resectable stage I–IIIB NSCLC.

    Materials and Methods
    In this retrospective study, patients with resectable stage I–IIIB NSCLC who underwent thoracic surgery from January 1, 2009, to December 31, 2018, from the Taiwan Cancer Registry were included. The last follow-up date was December 31, 2019. Patients were categorized into two groups according to whether they underwent preoperative metabolic imaging with fluorine 18 fluorodeoxyglucose PET/CT. Patients who did not undergo preoperative imaging were used as the control group. The primary outcome of interest was all-cause mortality. Patients in both groups were propensity score matched at a ratio of 1:1. Matching variables used were sex, age, histologic findings, American Joint Committee on Cancer clinical stage, cT stage, cN stage, current and past smoker history, adjuvant chemotherapy, adjuvant chemoradiation, Charlson comorbidity index, and hospital type. Survival curves were generated using the Kaplan-Meier method and compared using the log-rank test.

    Results
    In the matched cohort, 6754 patients (3349 men, mean age ± SD: 64 years ± 11) underwent PET/CT and 6754 did not (3362 men, mean age: 64 years ± 11). In adjusted analysis, patients with stage IIIA or IIIB NSCLC and preoperative PET/CT had a lower risk of death versus those without PET/CT (for stage IIIA: hazard ratio [HR] = 0.90 [95% CI: 0.79, 0.94], P = .02; for stage IIIB: HR = 0.80 [95% CI: 0.71, 0.90], P < .01). There was no improvement in a lower risk of death for patients with stage I–II NSCLC (after multivariable adjustment, the HR was 1.19 [95% CI: 0.89, 1.30], P = .65).

    Conclusion
    Use of preoperative PET/CT was associated with lower risk of death in patients with stage IIIA–IIIB non–small cell lung cancer compared with those without preoperative PET/CT.
    顯示於類別:[食品營養與保健生技學系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML93檢視/開啟


    在ASIAIR中所有的資料項目都受到原著作權保護.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋